Background: The present study was planned to formulate, characterize and evaluate the pharmacokinetics of a
novel “nanopolypill” comprising four commonly prescribed cardiovascular drugs, atorvastatin, aspirin, atenolol and candesartan.
Methods: The candidate drugs were loaded in Poly (DL-lactide-co-gycolide) (PLGA) by emulsion- diffusion-evaporation
method. The formulations were evaluated for their size, morphology, drug loading and in vitro release individually. Single
dose pharmacokinetic profiles of the nanoformulations alone and in combination, as a nanopolypill, were evaluated in
Results: The candidate drugs were encapsulated inside PLGA with entrapment efficiencies ranging from 27.8%, 33.5%,
47.5% and 62.9% for aspirin, candesartan, atenolol and atorvastatin respectively. The nanoparticles ranged in size from 50
to 169 nm. In vitro release profile of the nanoformulation showed 100% release by day 6 in the physiological pH 7.4 set
up with PBS (phosphate buffer saline) and by day 4-5 in the intestinal pH 1.2 and 8.0 set up SGF (simulated gastric fluid)
and SIF (simulated intestinal fluid) respectively. In pharmacokinetic analysis a sustained-release for 6 days and significant
increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of atorvastatin, atenolol,
aspirin and candesartan changed from 12.9 to 75.75 hours, 8.5 to 74.19 hours, 15.8 to 53.06 hours, and 12.6 to
94.92 hours respectively].
Conclusions: We have shown for the first time that encapsulating atorvastatin, aspirin, atenolol and candesartan into a
single nanoformulation, to get the “nanopolypill” is a feasible strategy which has a potential of decreasing pill burden.